Investigational^↗Metabolic^↗

Retatrutide^↗

Related names in cited records: LY3437943^↗

A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.^↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. ¹

This version supersedes public version 1.

Evidence summary

What the cited records say

ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.^↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Dated source history

July 20, 2026
Clinical trials
Retatrutide renal-impairment study record updated^↗
ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company.^↗
March 31, 2026
Regulatory
FDA warning letter names retatrutide and tirzepatide products^↗
FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide.^↗